Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey Conn

Showing results (31-40 of 416) with videos related to

Pageof 42
Sort By:
Neurobiology of Disease|October 1, 2013
Development of allosteric modulators of GPCRs for treatment of CNS disordersHilary Highfield Nickols, P Jeffrey Conn
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 15, 2015
Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?Rocco G Gogliotti, P Jeffrey Conn
Movement Disorders : Official Journal of the Movement Disorder Society|June 19, 2019
Roles of the M<sub>4</sub> acetylcholine receptor in the basal ganglia and the treatment of movement disordersMark S Moehle, P Jeffrey Conn
Pharmacology, Biochemistry, and Behavior|November 19, 2022
Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disordersShalini Dogra, Jason Putnam, P Jeffrey Conn
Annals of the New York Academy of Sciences|December 20, 2003
Modulation of excitatory transmission onto midbrain dopaminergic neurons of the rat by activation of group III metabotropic glutamate receptorsOrnella Valenti, Michael J Marino, P Jeffrey Conn
Molecular Brain|April 28, 2017
Targeting metabotropic glutamate receptors for novel treatments of schizophreniaJames Maksymetz, Sean P Moran, P Jeffrey Conn
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulataMarion Wittmann, Michael J Marino, P Jeffrey Conn
The Journal of Pharmacology and Experimental Therapeutics|September 2, 2005
Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytesYongqin Zhang, Alice L Rodriguez, P Jeffrey Conn
Trends in Pharmacological Sciences|November 13, 2019
Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological DisordersSean P Moran, James Maksymetz, P Jeffrey Conn
Annual Reports in Medicinal Chemistry|March 11, 2016
Drug Design Strategies for GPCR Allosteric ModulatorsP Jeffrey Conn, Scott D Kuduk, Darío Doller
Pageof 42

Showing results (31-40 of 416) with videos related to

Sort By:
Pageof 42
Neurobiology of Disease|October 1, 2013
Development of allosteric modulators of GPCRs for treatment of CNS disordersHilary Highfield Nickols, P Jeffrey Conn
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 15, 2015
Pharmacological Treatments for Autism Spectrum Disorder: Will Emerging Approaches Yield New Treatments?Rocco G Gogliotti, P Jeffrey Conn
Movement Disorders : Official Journal of the Movement Disorder Society|June 19, 2019
Roles of the M<sub>4</sub> acetylcholine receptor in the basal ganglia and the treatment of movement disordersMark S Moehle, P Jeffrey Conn
Pharmacology, Biochemistry, and Behavior|November 19, 2022
Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disordersShalini Dogra, Jason Putnam, P Jeffrey Conn
Annals of the New York Academy of Sciences|December 20, 2003
Modulation of excitatory transmission onto midbrain dopaminergic neurons of the rat by activation of group III metabotropic glutamate receptorsOrnella Valenti, Michael J Marino, P Jeffrey Conn
Molecular Brain|April 28, 2017
Targeting metabotropic glutamate receptors for novel treatments of schizophreniaJames Maksymetz, Sean P Moran, P Jeffrey Conn
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulataMarion Wittmann, Michael J Marino, P Jeffrey Conn
The Journal of Pharmacology and Experimental Therapeutics|September 2, 2005
Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytesYongqin Zhang, Alice L Rodriguez, P Jeffrey Conn
Trends in Pharmacological Sciences|November 13, 2019
Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological DisordersSean P Moran, James Maksymetz, P Jeffrey Conn
Annual Reports in Medicinal Chemistry|March 11, 2016
Drug Design Strategies for GPCR Allosteric ModulatorsP Jeffrey Conn, Scott D Kuduk, Darío Doller
Pageof 42